Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response

Approval of Ledipasvir/Sofosbuvir for the treatment of chronic hepatitis C (HCV) includes the truncation of therapy from 12 to 8 weeks in treatment naïve, non-cirrhotic patients with baseline HCV RNA levels <6 million IU/mL (6.8 log10 IU/mL). The aim of this study was to evaluate this clinical cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloherty, Gavin, Chevaliez, Stephane, Sarrazin, Christoph, Herman, Christine, Holzmayer, Vera, Dawson, George, Maasoumy, Benjamin, Vermehren, Johannes, Wedemeyer, Heiner, Feld, Jordan J., Pawlotsky, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071881/
https://www.ncbi.nlm.nih.gov/pubmed/27762283
http://dx.doi.org/10.1038/srep35410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071881/
https://www.ncbi.nlm.nih.gov/pubmed/27762283
http://dx.doi.org/10.1038/srep35410

Ejemplares similares